1AI 9.09% 1.0¢ algorae pharmaceuticals limited

the living cell technology paradox

  1. 223 Posts.
    lightbulb Created with Sketch. 2
    I have done alot of research over the past week on Living Cell Technology and what I have found is almost paradoxical.

    With new leadership in place, funding secured and the company in the midst of phase II clinical trials of its flagship product for treating Type I Diabetes, DIABECELL, I am quite baffled as to why the SP of LCT is at a 52 week low. Especially when you also consider its other product in the pipeline, NTCELL, which is targeting diseases such as Parkinson?s disease, Huntington?s disease, stroke and hearing loss.

    At a SP of 12 cents, this one is definitely flying under the radar if you ask me.
 
watchlist Created with Sketch. Add 1AI (ASX) to my watchlist
(20min delay)
Last
1.0¢
Change
-0.001(9.09%)
Mkt cap ! $16.87M
Open High Low Value Volume
1.0¢ 1.0¢ 1.0¢ $500 50K

Buyers (Bids)

No. Vol. Price($)
5 3533429 1.0¢
 

Sellers (Offers)

Price($) Vol. No.
1.1¢ 1744396 12
View Market Depth
Last trade - 13.34pm 28/06/2024 (20 minute delay) ?
1AI (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.